MAAT Fundamental Analysis - MAAT PHARMA SACA

Name: MAAT PHARMA SACA (MAAT) Stock
Brand: MAAT PHARMA SACA
Rating: 3.5 (3 reviews)

Fundamental Rating

Taking everything into account, MAAT scores 2 out of 10 in our fundamental rating. MAAT was compared to 78 industry peers in the Biotechnology industry. MAAT has a bad profitability rating. Also its financial health evaluation is rather negative. MAAT shows excellent growth, but is valued quite expensive already.

Quickly go to:

1. Profitability

1.1 Basic Checks

MAAT had negative earnings in the past year.

MAAT had a negative operating cash flow in the past year.

MAAT had negative earnings in each of the past 5 years.

In the past 5 years MAAT always reported negative operating cash flow.

1.2 Ratios

The Return On Assets of MAAT (-63.70%) is worse than 64.10% of its industry peers.

MAAT's Return On Equity of -375.32% is on the low side compared to the rest of the industry. MAAT is outperformed by 62.82% of its industry peers.

		Industry Rank	Sector Rank
ROA	-63.7%
ROE	-375.32%
ROIC	N/A

ROA(3y)-50.55%

ROA(5y)-38.35%

ROE(3y)-142.38%

ROE(5y)-96.6%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

MAAT's Gross Margin of 61.68% is in line compared to the rest of the industry. MAAT outperforms 58.97% of its industry peers.

In the last couple of years the Gross Margin of MAAT has declined.

MAAT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	61.68%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-9.66%

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

MAAT does not have a ROIC to compare to the WACC, probably because it is not profitable.

MAAT has more shares outstanding than it did 1 year ago.

MAAT has more shares outstanding than it did 5 years ago.

Compared to 1 year ago, MAAT has a worse debt to assets ratio.

2.2 Solvency

Based on the Altman-Z score of -0.95, we must say that MAAT is in the distress zone and has some risk of bankruptcy.

With a Altman-Z score value of -0.95, MAAT perfoms like the industry average, outperforming 46.15% of the companies in the same industry.

A Debt/Equity ratio of 1.43 is on the high side and indicates that MAAT has dependencies on debt financing.

With a Debt to Equity ratio value of 1.43, MAAT is not doing good in the industry: 60.26% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
Debt/Equity	1.43
Debt/FCF	N/A
Altman-Z	-0.95

ROIC/WACCN/A

WACC6.99%

2.3 Liquidity

A Current Ratio of 2.22 indicates that MAAT has no problem at all paying its short term obligations.

The Current ratio of MAAT (2.22) is comparable to the rest of the industry.

MAAT has a Quick Ratio of 2.21. This indicates that MAAT is financially healthy and has no problem in meeting its short term obligations.

MAAT has a Quick ratio (2.21) which is comparable to the rest of the industry.

		Industry Rank	Sector Rank
Current Ratio	2.22
Quick Ratio	2.21

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

MAAT shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -6.07%.

The Revenue has grown by 52.55% in the past year. This is a very strong growth!

Measured over the past years, MAAT shows a very strong growth in Revenue. The Revenue has been growing by 49.01% on average per year.

EPS 1Y (TTM)-6.07%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%5.31%

Revenue 1Y (TTM)52.55%

Revenue growth 3Y49.01%

Revenue growth 5YN/A

Sales Q2Q%41.02%

3.2 Future

Based on estimates for the next years, MAAT will show a quite strong growth in Earnings Per Share. The EPS will grow by 12.12% on average per year.

Based on estimates for the next years, MAAT will show a very strong growth in Revenue. The Revenue will grow by 125.82% on average per year.

EPS Next Y11.78%

EPS Next 2Y-4.46%

EPS Next 3Y12.12%

EPS Next 5YN/A

Revenue Next Year162.46%

Revenue Next 2Y73%

Revenue Next 3Y88.3%

Revenue Next 5Y125.82%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MAAT. In the last year negative earnings were reported.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MAAT. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

MAAT's earnings are expected to grow with 12.12% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-4.46%

EPS Next 3Y12.12%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

MAAT does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

MAAT PHARMA SACA

EPA:MAAT (11/24/2025, 9:14:53 AM)

4.04

+0.11 (+2.8%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)03-26 2025-03-26/amc

Earnings (Next)N/A N/A

Inst Owners44.96%

Inst Owner ChangeN/A

Ins Owners1.66%

Ins Owner ChangeN/A

Market Cap65.21M

Revenue(TTM)3.92M

Net Income(TTM)-31.13M

Analysts88.33

Price Target18.14 (349.01%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)-1.65%

PT rev (3m)-1.65%

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)5.15%

EPS NY rev (3m)3.23%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)7.04%

Revenue NY rev (3m)7.64%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	16.63
P/FCF	N/A
P/OCF	N/A
P/B	7.86
P/tB	11.98
EV/EBITDA	N/A

EPS(TTM)-2.15

EYN/A

EPS(NY)-2.27

Fwd EYN/A

FCF(TTM)-1.58

FCFYN/A

OCF(TTM)-1.53

OCFYN/A

SpS0.24

BVpS0.51

TBVpS0.34

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-63.7%
ROE	-375.32%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	61.68%
FCFM	N/A

ROA(3y)-50.55%

ROA(5y)-38.35%

ROE(3y)-142.38%

ROE(5y)-96.6%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-9.66%

GM growth 5YN/A

F-Score2

Asset Turnover0.08

Health

		Industry Rank	Sector Rank
Debt/Equity	1.43
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	45.37%
Cap/Sales	19.96%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	2.22
Quick Ratio	2.21
Altman-Z	-0.95

F-Score2

WACC6.99%

ROIC/WACCN/A

Cap/Depr(3y)108.1%

Cap/Depr(5y)117.91%

Cap/Sales(3y)39.59%

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-6.07%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%5.31%

EPS Next Y11.78%

EPS Next 2Y-4.46%

EPS Next 3Y12.12%

EPS Next 5YN/A

Revenue 1Y (TTM)52.55%

Revenue growth 3Y49.01%

Revenue growth 5YN/A

Sales Q2Q%41.02%

Revenue Next Year162.46%

Revenue Next 2Y73%

Revenue Next 3Y88.3%

Revenue Next 5Y125.82%

EBIT growth 1Y-25.89%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year-1.81%

EBIT Next 3Y8.03%

EBIT Next 5YN/A

FCF growth 1Y-29.17%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-33.07%

OCF growth 3YN/A

OCF growth 5YN/A

MAAT PHARMA SACA / MAAT.PA FAQ

What is the ChartMill fundamental rating of MAAT PHARMA SACA (MAAT.PA) stock?

ChartMill assigns a fundamental rating of 2 / 10 to MAAT.PA.

Can you provide the valuation status for MAAT PHARMA SACA?

ChartMill assigns a valuation rating of 0 / 10 to MAAT PHARMA SACA (MAAT.PA). This can be considered as Overvalued.

What is the profitability of MAAT stock?

MAAT PHARMA SACA (MAAT.PA) has a profitability rating of 0 / 10.

What is the earnings growth outlook for MAAT PHARMA SACA?

The Earnings per Share (EPS) of MAAT PHARMA SACA (MAAT.PA) is expected to grow by 11.78% in the next year.

MAAT PHARMA SACA (MAAT.PA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

MAAT PHARMA SACA / MAAT.PA FAQ

What is the ChartMill fundamental rating of MAAT PHARMA SACA (MAAT.PA) stock?

Can you provide the valuation status for MAAT PHARMA SACA?

What is the profitability of MAAT stock?

What is the earnings growth outlook for MAAT PHARMA SACA?